What is Ajanta Pharma’s revenue and profit?

In FY25, the company’s total revenue was ₹4,648 crore, and net profit was ₹920 crore.

Does Ajanta Pharma have debt?

No, the company has no long-term debt, which keeps its financial position strong.

What is the P/E ratio of Ajanta Pharma?

Its P/E ratio is ~34 as of December 2050

Stock

Dividend Stocks | Share Price Target

Ajanta Pharma Share Price Target 2026, 2027, 2030, 2040, 2050

Read More Ajanta Pharma Share Price Target 2026, 2027, 2030, 2040, 2050
Dividend Stocks | Share Price Target

Astrazeneca Pharma India Share Price Target 2026, 2027, 2030, 2040, 2050

Read More Astrazeneca Pharma India Share Price Target 2026, 2027, 2030, 2040, 2050
Dividend Stocks | Share Price Target

Acutaas Chemicals Share Price Target 2026, 2027, 2030, 2040, 2050

Read More Acutaas Chemicals Share Price Target 2026, 2027, 2030, 2040, 2050
Share Price Target | Dividend Stocks

Blue Jet Healthcare Share Price Target 2026, 2027, 2030, 2040, 2050

Read More Blue Jet Healthcare Share Price Target 2026, 2027, 2030, 2040, 2050
Share Price Target | Dividend Stocks

Zydus Lifesciences Share Price Target 2026, 2027, 2030, 2040, 2050

Read More Zydus Lifesciences Share Price Target 2026, 2027, 2030, 2040, 2050
Share Price Target

Indegene Share Price Target 2026, 2027, 2030, 2040, 2050

Read More Indegene Share Price Target 2026, 2027, 2030, 2040, 2050
Share Price Target

KSH International Share Price Target 2026, 2027, 2030

Read More KSH International Share Price Target 2026, 2027, 2030
Share Price Target | Dividend Stocks

Abbott India Share Price Target 2026, 2027, 2030, 2040, 2050

Read More Abbott India Share Price Target 2026, 2027, 2030, 2040, 2050
Share Price Target | Dividend Stocks

Emcure Pharma Share Price Target 2026, 2027, 2030, 2040, 2050

Read More Emcure Pharma Share Price Target 2026, 2027, 2030, 2040, 2050